Clinical Trial

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

Study acronym: GABRINOX2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-03-30 -> 2026-12-30 2026-04-16
minor Completion pushed: 2027-10-30 -> 2028-06-30 2026-04-16
Trial Details
NCT Number NCT05065801
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Metastatic Pancreatic Cancer
Enrollment 162 participants
Start Date 2022-01-11
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15